#United States #San Diego #Halozyme Therapeutics #ENHANZE #rHuPH20

Halozyme Therapeutics Reports Strong Q1 2025 Results and Raises Financial Guidance

Halozyme Therapeutics, Inc. recently celebrated a strong start to 2025, announcing impressive financial results for the first quarter, which ended on March 31. As a result, the company has increased its financial guidance for the year, demonstrating robust growth across essential metrics.

Financial Highlights

In the first quarter of 2025, Halozyme reported total revenues of $264.9 million, a remarkable 35% increase compared to the preceding year when revenues stood at $195.9 million. This significant growth was primarily driven by a 39% rise in royalty revenues, amounting to $168.2 million, attributed to popular products like VYVGART® Hytrulo, DARZALEX® SC, and Phesgo®.

Further, the company noted a considerable net income increase, up 54% year-over-year to reach $118.1 million. Adjusted EBITDA also saw a promising rise of 40%, totaling $162 million.

In the wake of these results, Halozyme announced an elevated financial outlook for the remainder of the year, anticipating total revenues between $1.2 billion and $1.28 billion, reflecting 18%-26% growth over the previous year. Adjusted EBITDA is now projected to fall between $790 million and $840 million, signifying expected growth of 25%-33%. Additionally, the forecast for non-GAAP diluted earnings per share (EPS) was adjusted to a range of $5.30 to $5.70, projecting a 25%-35% increase.

Corporate Updates

Dr. Helen Torley, President and CEO of Halozyme, emphasized the positive momentum as the company boasts a diversified product portfolio. Halozyme's three primary blockbuster brands, Darzalex SC, Phesgo, and VYVGART Hytrulo, are performing exceptionally well in their approved indications. The recent launch of four new products and expanding collaborations with partners like Roche and Takeda signal even more growth potential.

To further enhance shareholder value, Halozyme has introduced a new share repurchase program totaling $250 million, under a previously approved $750 million plan which was initiated in February 2024. In addition, the company is proactive in safeguarding its intellectual property, as evidenced by its patent infringement lawsuit against Merck Sharp & Dohme Corp. regarding its proprietary drug delivery technology.

Recent Partner Achievements

Halozyme's partnership highlights are noteworthy, with several collaborative agreements advancing towards product approvals. Notable mentions include:

• - Roche's successful recommendation from the European Medicines Agency (EMA) for Phesgo®, which will soon allow administration in non-clinical settings.
• - argenx's positive opinion from EMA and FDA approval for VYVGART® Hytrulo, marking a significant step in treating chronic inflammatory demyelinating polyneuropathy.
• - Janssen's approval for the RYBREVANT® SC formulation in Europe as a frontline therapy for non-small cell lung cancer patients.

These accomplishments underscore the increasing viability of Halozyme's ENHANZE® technology, which facilitates subcutaneous drug delivery, thereby elevating patient experience and outcome.

Long-Term Vision

Looking beyond 2025, Halozyme's long-term growth trajectory appears promising, buoyed by ongoing product development and collaborations. The company continues to monitor advances in its pipeline, including drugs in Phase 3 trials and the execution of development agreements with ENHANZE partners.

As Halozyme Therapeutics enters the second quarter of 2025, it remains focused on sustaining growth and maximizing shareholder value through strategic product launches and robust marketing efforts. The proactive steps being taken today are setting the stage for a successful future and reflecting a commitment to improving patient care across their extensive product lines.

In conclusion, Halozyme's recent performance not only illustrates its capacity for growth but also showcases its strategic approach to enhancing patient outcomes and participating in meaningful partnerships across the industry.